Inflarx NV logo

IFRX - Inflarx NV News Story

$3.65 -0.1  -1.4%

Last Trade - 8:17pm

Sector
Healthcare
Size
Small Cap
Market Cap £115.7m
Enterprise Value £45.9m
Revenue £n/a
Position in Universe 4718th / 6847

BRIEF-Inflarx Completes Enrollment In Vilobelimab (Ifx-1) European Phase Ii Study In Anca-Associated Vasculitis

Tue 5th January, 2021 12:38pm
Jan 5 (Reuters) - Inflarx NV  IF0G.DE :
    * INFLARX COMPLETES ENROLLMENT IN VILOBELIMAB (IFX-1)
EUROPEAN
PHASE II STUDY IN ANCA-ASSOCIATED VASCULITIS

Source text for Eikon:  ID:nGNX3CPqvt 
Further company coverage:  IF0G.DE 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.